Gastroprotective effect of MX1 (a novel salt of the active metabolite of roxatidine with a complex of bismuth and citric acid) against stress ulcers in rats

Journal of Pharmacy and Pharmacology

Volumn 49, Issue 8, 1997, Pages 791-795

  Marazova, K ^a   Klouchek, E ^a   Popov, A ^a   Ivanov, Ch ^b   Krushkov, I ^a  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^b University in Sofia   (Bulgaria)

Author keywords

[No Author keywords available]

Indexed keywords

BISMUTH; BISMUTH CITRATE; CITRIC ACID; DRUG METABOLITE; MX 1; ROXATIDINE; UNCLASSIFIED DRUG; ANTACID AGENT; ANTIULCER AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; MX(1) COMPLEX; ORGANOMETALLIC COMPOUND; PIPERIDINE DERIVATIVE; ROXATIDINE ACETATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MIXTURE; IMMOBILIZATION STRESS; INTRAGASTRIC DRUG ADMINISTRATION; MALE; MORPHOMETRICS; NONHUMAN; RAT; STOMACH PROTECTION; STRESS ULCER; ANIMAL; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; EXERCISE; PEPTIC ULCER; SECRETION; STOMACH MUCOSA; WISTAR RAT;

ANIMALS; ANTACIDS; ANTI-ULCER AGENTS; DRUG COMBINATIONS; GASTRIC MUCOSA; HISTAMINE H2 ANTAGONISTS; MALE; ORGANOMETALLIC COMPOUNDS; PEPTIC ULCER; PIPERIDINES; RATS; RATS, WISTAR; RESTRAINT, PHYSICAL;

EID: 0030612542     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.1997.tb06114.x     Document Type: Article

References (17)

1. Blaser, M. J. (1992) Helicobacter pylori: its role in disease. Clin. Infect. Dis. 15: 386-391
2. Feldman, M., Burton, M. E. (1990) Histamine2-receptor antagonists. Standard therapy for acid-peptic disease. N. Engl. J. Med. 323: 1749-1755
3. Graham, D. Y., Ginger, M. L., Evans, D. G. Jr, Klein, P. D. (1991) Effect of triple therapy (antibiotics and bismuth) on duodenal ulcer healing: a randomized controlled trial. Ann. Intern. Med. 115: 266-269
4. Graham, D. Y., Lew, G. M., Klein, P. D., Evans, D. G., Evans, D. J., Saeed, Z. A. (1992) Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric and duodenal ulcers: a randomized, controlled study. Ann. Intern. Med. 116: 705-708
5. Hentschel, E., Brandstatter, G., Dragosics, B., Hirschl, A. M., Nemec, H., Schutze, K., Taufer, M., Wurzer, H. (1993) Effect of ranitidine and amoxycillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N. Engl. J. Med. 328: 308-312
6. Hudson, N., Murrey, F. E., Codle, A. T., Turnbull, G. M., Lettis, S., Hawkey, C. J. (1992) Ranitidine bismuth citrate in the prevention of aspirin-induced gastric mucosal injury. Gut 33 (Suppl.): V47
7. 1). J. Pharm. Pharmacol. 48: 297-301
8. Jensen, D. M., Cheng, S., Kovacs, T. O. G., Randall, G., Jensen, M.-E., Reedy, T., Frankl, H., Machicado, G., Smith, J., Silpa, M., VanDeventer, G. (1994) A controlled study of ranitidine for the prevention of recurrent hemorrhage from duodenal ulcer. N. Engl. J. Med. 330: 382-386
9. Labenz, J., Borsch, G. (1994) Evidence for the essential role of Helicobacter pylori in gastric ulcer disease. Gut 35: 19-22
10. Miller, T. A. (1987) Mechanisms of stress-related mucosal damage. Am. J. Med. (Suppl. 6A): 8-14
11. Peterson, W. L., Sontag, S. J., Ciociola, A. A. (1995) Ranitidine bismuth citrate plus clarithromycin is effective in the eradication of Helicobacter pylori and prevention of duodenal ulcer relapse. Gastroenterology 108 (Suppl. A): 190
12. Stables, R., Campbell, C. J., Clayton, N. M., Clitherow, J. W., Grinham, C. J., McColm, A. A., McLaren, A., Trvethick, M. A. (1993) Gastric anti-secretory, mucosal protective, anti-pepsin and anti-Helicobacter properties of ranitidine bismuth citrate. Aliment. Pharmacol. Ther. 7: 237-246
13. Takagi, K., Kasuja, J., Watanabe, K. (1964) Studies on the drugs for peptic ulcers. A reliable method for producing stress ulcers in rats. Chem. Pharm. Bull. 12: 456-472
14. Taylor, D. N., Blaser, M. J. (1991) The epidemiology of Helicobacter infection. In: Marshall, B. J., McCallum, R. W., Guerrant, R. L. (eds) Helicobacter pylori in Peptic Ulceration and Gastritis, Boston, Blackwell Scientific Publications, pp 127-139
15. Tytgat, G. N. J., Rauws, E. A. J. (1990) Campylobacter pylori and its role in peptic ulcer disease. Gastroenterol. Clin. North Am. 19: 183-196
16. Wagstaff, A. J., Banfield, P., Monk, J. P. (1988) Colloidal bismuth subcitrate: a review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in peptic ulcer disease. Drugs 36: 132-157
17. Walsh, J. H., Peterson, W. L. (1995) The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N. Engl. J. Med. 333: 984-991.